BNTX · PEAD → 22

BioNTech reported Q3 2026 EPS of $1.94 on 2026-11-03, beating the $0.85 consensus by $1.09 (+128.2%).

Print-day reaction was −0.70% versus the prior close, a muted slip despite a substantial EPS beat. The overnight gap into T+1 recovered sharply, adding +2.67% to the opening print, suggesting after-hours sentiment favoured the upside surprise. Over trading days 1–3, however, the stock drifted −3.52%, erasing the gap and then some, reversing the overnight optimism. Cumulative abnormal return of +2.21% versus SPY.US sits inside the ±3% neutral band, yielding a PEAD verdict of none with conviction 22; the holding window runs through 2027-01-29.